Lisata Therapeutics (LSTA) vs China SXT Pharmaceuticals (SXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lisata Therapeutics is the larger company by market cap ($647,451 vs $273,955), about 2.4 times the size, while China SXT Pharmaceuticals is growing revenue faster (-34.6% vs -83.0%). China SXT Pharmaceuticals converts more of its revenue into profit, with a net margin of -545.2% versus -9756.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LSTA | SXTC |
|---|---|---|
| Share price | $0.8989 | $2.65 |
| Market cap | $647.45K | $273.95K |
| 1-day change | -1.22% | +2.12% |
| YTD return | -51.67% | — |
| 1-year return | -54.14% | — |
| 5-year return | -93.89% | — |
| EPS (TTM) | $-28.20 | $-73,040.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $170.00K | $1.14M |
| Revenue growth (YoY) | -83.00% | -34.63% |
| Net income (latest FY) | $-16.59M | $-6.21M |
| Gross margin | — | 21.85% |
| Operating margin | -10711.18% | -625.89% |
| Net margin | -9756.47% | -545.24% |
| 52-week high | $76.05 | $8,376,000.00 |
| 52-week low | $0.85 | $2.52 |
| Distance from 52-week high | -98.82% | -100.00% |
| Analyst consensus | none | — |
| Average volume | 13.46K | 234.25K |
| Shares outstanding | 720.27K | 103.58K |
| Employees | 21 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lisata Therapeutics is about 2.4 times larger than China SXT Pharmaceuticals by market value ($647.45K vs $273.95K).
- China SXT Pharmaceuticals is more profitable, keeping -545.2 cents of every revenue dollar as net income versus -9756.5 cents for Lisata Therapeutics.
- China SXT Pharmaceuticals grew revenue faster in its latest fiscal year (-34.63% vs -83.00%).
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About China SXT Pharmaceuticals
SXTC stock →China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
LSTA vs SXTC FAQ
Which is bigger, Lisata Therapeutics or China SXT Pharmaceuticals?
Lisata Therapeutics (LSTA) is larger, with a market capitalization of $647.45K compared with $273.95K for China SXT Pharmaceuticals (SXTC).
Are Lisata Therapeutics and China SXT Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.